UK markets closed

NIKKEI 225
38,274.05
-131.61(-0.34%)
HANG SENG
17,763.03
+16.12(+0.09%)
CRUDE OIL
79.06
+0.06(+0.08%)
GOLD FUTURES
2,330.80
+19.80(+0.86%)
DOW
37,903.29
+87.37(+0.23%)
Bitcoin GBP
46,220.92
-2,155.54(-4.46%)

Family finances

Who is the breadwinner in your family and does it matter?

MRK Dec 2026 135.000 call

OPR - OPR Delayed price. Currency in USD

Add to watchlist

18.50

0.00

(0.00%)

As of 02:32PM EDT. Market open.

Business Wire
Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival (OS) as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
RAHWAY, N.J., May 01, 2024--Merck Announces KEYNOTE-811 Trial Met Dual Primary Endpoint as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or GEJ Cancer
Insider Monkey
Merck & Co., Inc. (NYSE:MRK) Q1 2024 Earnings Call Transcript
Merck & Co., Inc. (NYSE:MRK) Q1 2024 Earnings Call Transcript April 25, 2024 Merck & Co., Inc. beats earnings expectations. Reported EPS is $2.07, expectations were $1.94. Merck & Co., Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Thank […]
Business Wire
Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults
RAHWAY, N.J., April 29, 2024--Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults